SCHEMBL13291219

SCHEMBL13291219

N#Cc1ccc2oc(C(=O)Nc3ccc(Cl)cn3)c(N)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ RAB9A P51151 9/20 0.47
▸ NPC1 O15118 7/20 0.47
▸ NFKB1 P19838 3/20 0.47
▸ NFKB2 Q00653 3/20 0.47
▸ RELA Q04206 3/20 0.47
▸ TSHR P16473 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ POLB P06746 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TMPRSS4 Q9NRS4 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13291212 0.86 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2948037 0.84 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13291214 0.84 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13291210 0.84 SMN1; SMN2 (0.56) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2953856 0.83 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL13291218 0.81 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2944950 0.81 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2948943 0.80 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2947449 0.80 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1NFKB1NFKB2
SCHEMBL2946788 0.79 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885RAB9A 4692/4885NPC1 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback